Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFF hire

This article was originally published in The Rose Sheet

Executive Summary

Dennis Meany tapped as senior VP, general counsel and secretary, effective Jan. 1, fragrance and flavor supplier announces. Currently associate general counsel, Meany will succeed Stephen Block, who plans to retire at the end of this year, the firm notes. Meany previously worked as VP, general counsel and secretary of Bush Boake Allen, which was acquired by IFF in 2000 (1"The Rose Sheet" Oct. 2, 2000, p. 11)...

You may also be interested in...



IFF/Bush Boake Allen Combo Creates $970 Mil. Fragrance Supplier Business

International Flavors and Fragrances' acquisition of Bush Boake Allen will result in a $970 mil. fragrance supplier business. The deal will merge IFF's $850 mil. and BBA's $120 mil. operations, CEO Richard Goldstein maintained during a Sept. 26 conference call.

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

UsernamePublicRestriction

Register

RS011634

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel